Efficacy of Nandhi Mezhugu for Treating Itchy Hives (Urticaria)_ A Clinical Trial

An Open Label Single Arm Clinical Trial to evaluate the Effectiveness of Siddha Poly Herbomineral Formulation NANDHI MEZHUGU in the management of kaanakadi (Urticaria) Among Patients Reporting Ayothidoss Pandithar Hospital, National Institute of Siddha - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/107193

Enrollment

Registered

2026-03-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L509- Urticaria, unspecified

Interventions

Intervention1: Nandhi Mezhugu: Internal Medicine: Dose:130 mg/ Twice a day Vehicle: Palm jaggery Duration: 1 Mandalam Drug Holiday: 3 days once a week Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Participants with UAS7 disease activity score bands range 16-27 based on clinical signs of pruritis(itching) and wheal formation (hives)

Exclusion criteria

Exclusion criteria: Evidence of any skin condition other than urticaria, Angioedema, Narcotic addicts, Pregnancy and Lactation, Any other systemic illness, Known case of Diabetes mellitus, Known case of Hypertension

Design outcomes

Primary

Measure	Time frame
Significant reduction in clinical signs and symptoms based on Urticaria Activity Score over 7 days (UAS7) and clinical laboratory blood parameters such as IGE,AEC,ESR,CRPTimepoint: 18 Months	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactProf Dr Murugesan S

National Institute of Siddha

ss.drss@gmail.com9841108269

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026